ADRB2 and liposarcoma: Indeed, the combination of propranolol with all tested chemotherapeutics achieved a synergistic inhibition of proliferation in SW-872 liposarcoma cells, further suggesting a functional role of β-AR signalling in proliferation and in the response to chemotherapeutics in these cells.